MedChemExpress LLC (MCE)

MedChemExpressModel Polyinosinic-polycytidylic acid - 24939-03-5

SHARE
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis[1][2].
Most popular related searches

MCE products for research use only. We do not sell to patients.

Polyinosinic-polycytidylic acid

MCE China:Polyinosinic-polycytidylic acid

Brand:MedChemExpress (MCE)

Cat. No.HY-107202

CAS:24939-03-5

Synonyms:Poly(I:C)

Purity:99.4%

Storage:Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month

Shipping:Room temperature in continental US; may vary elsewhere.

Description:Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.

In Vitro:Polyinosinic-polycytidylic acid (0.5-5 μg/mL, 3-24 h) induces a dose- and time-dependent increase in paracellular permeability of immortalized airway epithelial cells[4]. Polyinosinic-polycytidylic acid (5 μg/mL, 24 h) does not have cytotoxicity to 16HBE14o- cells[4]. Polyinosinic-polycytidylic acid (5 μg/mL, 6 h) induces disruption of epithelial apical junctional complexes (AJCs) and tight junctions (TJs) in 16HBE14o- cells[4].

In Vivo:Polyinosinic-polycytidylic acid (2.5-10 mg/mL, Stereotaxic injection, single dose) induces a sustained inflammatory reaction in the substantia nigra (SN) and in the dorsolateral striatum. [2]. Polyinosinic-polycytidylic acid (10 μg/mouse, Intraperitoneal injection, single dose) decreases lung tumor growth in mice[3]. Polyinosinic-polycytidylic acid (1.25 mg/kg, Intraperitoneal injection, single dose) exerts therapeutic effects against cerebral I/R injury through the downregulation of TLR4/MyD88 signaling via TLR3 in MCAO model mice[5].

IC50 & Target:Bcl-2 Bax IL-17A IL-13 HSP70

Hot selling product:Idarubicin (hydrochloride)  | Bumetanide  | SU14813  | Pravastatin (sodium)  | Berotralstat  | Reserpine  | D-Glucose 6-phosphate (disodium salt)  | Carbamazepine  | 5-Fluoroorotic acid  | AR-C118927XX

Trending products:Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References:

[1]. Cheng Y, Xu F. Anticancer function of polyinosinic-polycytidylic acid [J]. Cancer biology & therapy, 2010, 10(12): 1219-1223.

[2]. Deleidi M, Hallett P J, Koprich J B, et al. The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration [J]. Journal of Neuroscience, 2010, 30(48): 16091-16101.

[3]. Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer [J]. The Journal of Immunology, 2012, 188(11): 5357-5364.

[4]. Rezaee F, Meednu N, Emo J A, et al. Polyinosinic: polycytidylic acid induces protein kinase D–dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells [J]. Journal of Allergy and Clinical Immunology, 2011, 128(6): 1216-1224. e11.

[5]. Wang P F, Fang H, Chen J, et al. Polyinosinic-polycytidylic acid has therapeutic effects against cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via TLR3 [J]. The Journal of Immunology, 2014, 192(10): 4783-4794.

[6]. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732-738.  [Content Brief]

[7]. Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun. 2002;293(5):1364-1369.  [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
•   It has a professional experimental center and strict quality control and verification system;
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
•   The biological activity of the products has been verified by the experiments of customers in various countries;
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。